Article

Updated OCT system gains 510(k) clearance

Optovue has received FDA 510(k) clearance for an updated version of its proprietary spectral-domain optical coherence tomography system (RTVue XR FD-OCT system).

Fremont, CA-Optovue has received FDA 510(k) clearance for an updated version of its proprietary spectral-domain optical coherence tomography system (RTVue XR FD-OCT system).

The new version increases the number of A-scans per second to 70,000. It is scheduled to be available in the third quarter of this year.

“This FDA clearance affirms [the proprietary OCT system’s] position as the market leader, now with the fastest scan speed of any FDA-cleared device available,” said Jay Wei, Optovue chief executive officer. “We continue to leverage our experience in OCT product development and Fourier-domain technology to serve the needs of physicians and patients.”

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) CCOI's new CEO Malvina Eydelman, MD, outlines her mission and vision for the organization
CIME 2025: Neda Shamie, MD, on expanding options in pharmacological presbyopia management
At CIME 2025, Neda Shamie, MD, answers questions about Demodex blepharitis
(Image credit: Ophthalmology Times) ASCRS 2025: Deb Ristvedt, DO, on medications, lasers, and lifestyle in glaucoma management
(Image credit: Ophthalmology Times) ASCRS 2025: Mark Lobanoff, MD, on making the move to office-based surgery
Barsha Lal, PhD, discusses the way low dose atropine affects accommodative amplitude and dynamics at the 2025 ARVO meeting
(Image credit: Ophthalmology Times) NeuroOp Guru: When eye findings should prompt neuroimaging in suspected neuro-Behcet disease
© 2025 MJH Life Sciences

All rights reserved.